直肠腺癌新辅助长程放化疗期间患者报告呕吐、干呕、恶心及止吐药使用的前瞻性队列研究
单中心非随机前瞻性队列纳入33例接受长程新辅助放疗联合同期5-氟尿嘧啶类化疗的直肠腺癌成人患者,每日记录症状与用药至治疗结束后7天,共收集1407天数据。患者报告呕吐7例(21%)、干呕5例(15%)、恶心21例(64%),无患者接受预防性止吐药;呕吐中位天数为2天,所有受累患者累计22天(占可评估日的1.6%)。作者认为该场景下5-HT3受体拮抗剂预防似乎不必要。
要点
- 呕吐累计天数仅占可评估日的1.6%,支持不常规预防性使用5-HT3RA。
- 恶心报告率64%,高于呕吐与干呕,需关注恶心管理。
- 呕吐与未呕吐患者间PTV及小肠V15Gy、V45Gy、V50Gy体积无差异。
核心结论
- 长程新辅助放化疗期间患者报告呕吐的累计天数占比仅1.6%,该场景下5-HT3RA预防似乎不必要。
研究设计与样本
- 单中心非随机前瞻性队列研究,纳入33例可评估的接受长程新辅助放疗联合同期5-氟尿嘧啶类化疗的直肠腺癌成人患者。
- 患者每日记录症状与用药直至治疗结束后7天,共收集1407天患者报告数据。
主要发现
- 呕吐由7例(21%)报告,干呕由5例(15%)报告,恶心由21例(64%)报告。
- 无患者接受预防性止吐药;呕吐中位天数为2天,所有受累患者累计22天,占1407个可评估日的1.6%。
- 呕吐与未呕吐患者之间PTV及小肠V15Gy、V45Gy、V50Gy体积无差异。
临床怎么用
- 该人群中可不常规给予5-HT3RA预防性止吐,以避免其所致便秘风险,但仍需关注高发的恶心症状。
局限性
- 单中心、非随机、样本量小(33例可评估),结果外推需谨慎。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND AND PURPOSE: Antiemetic guidelines suggest daily prophylaxis with a serotonin3 receptor antagonist (5-HT3RA) as an option for patients receiving long-course neoadjuvant radiation therapy and concurrent 5-fluorouracil-based chemotherapy for rectal cancer, despite the risks that 5-HT3RA-induced constipation may pose. We explored the incidence of patient-reported vomiting, retching, nausea and antiemetic intake among patients in this setting to determine if these risks are justified. MATERIALS AND METHODS: We carried out a single-centre non-randomised prospective cohort study of adult patients receiving long-course neoadjuvant radiation therapy and concurrent 5-fluorouracil-based chemotherapy for rectal adenocarcinoma. Patients recorded symptoms and medication intake daily until 7 days following treatment completion. RESULTS: From 33 evaluable patients, we collected 1407 days of patient-reported data. Vomiting was reported by 7 patients (21%), retching by 5(15%) and nausea by 21(64%). No patients were administered prophylactic antiemetics. The median number of days with vomiting was 2, and the cumulative number of days for all affected patients was 22 (1.6% of 1407 evaluable days). There were no differences in PTV or small bowel loop V15Gy, V45Gy and V50Gy volumes between patients that did and did not vomit. CONCLUSIONS: The cumulative incidence of days with vomiting was only 1.6%. 5-HT3RA prophylaxis during long-course neoadjuvant treatment seems unnecessary.
引用
- Dennis K, Zeng L, De Angelis C, et al. A prospective cohort study of patient-reported vomiting, retching, nausea and antiemetic use during neoadjuvant long-course radiation therapy and concurrent 5-fluorouracil-based chemotherapy for rectal adenocarcinoma. Clin Transl Radiat Oncol. 2018. PMID: 29682620. doi:10.1016/j.ctro.2018.04.001
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。